Transfusion-Dependent β-Thalassemia (TDT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 β-thalassemia is typically a result of a monogenic disorder, primarily caused by a decrease or absence in the synthesis of the β-globin chain. This particular chain is vital to adult hemoglobin (HbA, α2β2). Consequently, an imbalance occurs between α and β chains, accumulating unattached α-globin chains. These excess α-globin chains form insoluble Hemi-chromes within erythrocyte precursor cells, causing damage to the erythrocyte membrane. This damage, in turn, triggers severe intramedullary erythrocyte apoptosis, referred to as ineffective erythropoiesis (IE). As a result, red blood cells (RBCs) experience a significantly shortened lifespan due to extra-medullary hemolysis, leading to severe anemia. The most severe manifestation of this condition, known as transfusion-dependent β-thalassemia (TDT), is characterized by profound anemia. To maintain adequate hemoglobin levels, individuals with TDT require lifelong and regular blood transfusions. However, these transfusions pose a considerable risk of causing progressive multi-organ damage due to the inevitable iron overload. If left untreated, β-thalassemia can inflict harm on various organs, potentially resulting in fatal consequences.

·       The estimated prevalence of β-thalassemia cases in the United States varies between 1.5 to 2.6 cases per 100,000 individuals, depending on geographic factors.

 

Thelansis’s “Transfusion-Dependent β-Thalassemia (TDT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Transfusion-Dependent β-Thalassemia (TDT) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Transfusion-Dependent β-Thalassemia (TDT) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Transfusion-Dependent β-Thalassemia (TDT) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Transfusion-Dependent β-Thalassemia (TDT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Transfusion-Dependent β-Thalassemia (TDT), Transfusion-Dependent β-Thalassemia (TDT) market outlook, Transfusion-Dependent β-Thalassemia (TDT) competitive landscape, Transfusion-Dependent β-Thalassemia (TDT) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)